Benitec Biopharma Inc. (BNTC): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 08:02 ET
- Event date
- 2026-11-12
- Accession no.
- 0001193125-26-459339
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Benitec reports quarterly results, BB-301 clinical update and fiscal year-end change
Benitec reported a $12.9 million net loss for the quarter ended September 30, 2026, versus $9.0 million a year earlier. It disclosed a 100% responder rate across BB-301 Cohort 1 and Cohort 2 patients and said its pivotal trial remains on track for mid-2027. The board changed the fiscal year-end to December 31; a transition Form 10-K will cover July 1, 2026 through December 31, 2026.
- Net loss was $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million a year earlier.
- BB-301 interim results showed a 100% responder rate across Cohort 1 and Cohort 2; no Serious Adverse Events were reported to date.
- Benitec remains on track to begin the BB-301 pivotal trial in mid-2027.
- On November 12, 2026, the board changed the fiscal year-end from June 30 to December 31, effective the same date.
earningsproductgovernance
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
The company amended its articles of incorporation or bylaws without a shareholder vote that was previously disclosed, or changed its fiscal year. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | bntc-20261112.htm |
| EX-99.1 | EX-99.1 | bntc-ex99_1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.